AxioMx this week launched its new custom recombinant antibody discovery and development services, which include epitope mapping and antigen design as well as antibody screening, optimization, and production.
The company's proprietary phage display libraries and "rapid liquid" screening and affinity maturation methods enable it to produce monoclonal antibodies in as little as eight weeks, it said.